Abstract. Chromatin remodelling can be involved in some of the epigenetic modifications found in tumor cells. One of the mechanisms at the basis of chromatin dynamics is likely to be synthesis and incorporation of replacement histone variants, such as the H1˚ linker histone. Regulation of the expression of this protein can thus be critical in tumorigenesis. In developing brain, H1˚ expression is mainly regulated at the post-transcriptional level and RNA-binding proteins (RBPs) are involved. In the past, attention mainly focused on the whole brain or isolated neurons and little information is available on H1˚ expression in other brain cells. Even less is known relating to tumor glial cells. In this study we report that, like in maturing brain and isolated neurons, H1˚ synthesis sharply increases in differentiating astrocytes growing in a serum-free medium, while the corresponding mRNA decreases. Unexpectedly, in tumor glial cells both H1˚ RNA and protein are highly expressed, in spite of the fact that H1˚ is considered a differentiation-specific histone variant. Persistence of H1˚ mRNA in oligodendroglioma cells is accompanied by high levels of H1˚ RNA-binding activities which seem to be present, at least in part, also in actively proliferating, but not in differentiating, astrocytes. Finally, we report that oligodendroglioma cells, but not astrocytes, release H1˚ protein into the culture medium by shedding extracellular vesicles. These findings suggest that deregulation of H1˚ histone expression can be linked to tumorigenesis.

Introduction

The transcriptional potential of the cell nucleus is determined by availability of transcription factors and by the structural organization of genes in the context of chromatin. Even in terminally differentiated cells, specific regions of chromatin must be remodelled to allow transcription activation or repression in response to intra- and/or extracellular signals. Linker histone H1 binds DNA in between nucleosomes and regulates chromatin higher order structures (1-5), thus also mediating differential gene expression (6,7).

The H1 family is the most divergent among histone proteins, with at least 11 different genes in humans, most of which form a cluster on chromosome 6 (chromosome 13 in mouse, and chromosome 17 in the rat) (8). In general, it is possible to distinguish between two types of H1 histone genes: clustered- and single-genes. Moreover, this peculiar distribution of H1 genes is conserved among human, mouse and rat. Each H1 protein subtype has been also suggested to have specific distribution and function in chromatin (7,9,10). In comparison with the intermediate chromatin condensing activity of H1.3, for example, other subtypes have been classified as weak condensers (H1.1 and H1.2) and strong condensers (H1.0, H1.4, H1.5, and H1.x) (10,11).

Functional differences among subtypes have been, however, difficult to identify since they probably have redundant activities in development (9,12). It is clear that linker histones are highly mobile in chromatin and that they interact with both cytosolic and nuclear proteins, thus regulating a variety of cellular processes (10); they are also able to promote epigenetic silencing of genes, by regulating both DNA methylation and histone H3 methylation (13). H1˚ is a linker histone subtype the expression of which has been mostly correlated with terminal differentiation (14,15).

In developing rat brain, the concentration of H1˚ mRNA decreases in vivo between the embryonal day 18 (E18) and the postnatal day 10 (P10), with inverse correlation to protein accumulation (16); the concentration of H1˚ mRNA also decreases in isolated neurons, between the second and the fifth day of culture in a serum-free medium, while an active synthesis of
the corresponding proteins can be observed (17). The H1° gene is transcribed at the same rate at any stage studied, suggesting that it is regulated mainly at post-transcriptional level (17). Since post-transcriptional control processes are mediated by several classes of RNA-binding proteins (18-21), it was likely that developing rat brain contained mRNA-binding factors involved in H1° mRNA binding and regulation. We indeed already reported identification of a variety of H1° mRNA-binding proteins probably involved in the regulation of H1° mRNA metabolism (22-30).

A number of cell types can shed into the environment microvesicles of different sizes (MVs) under both physiological and pathological conditions (31-35). MVs contain a wide array of biological molecules, such as proteins, lipids, DNA, microRNAs and mRNAs, and have been suggested to act as means of cell-to-cell communication (36). MVs can trigger in target cells various events, including apoptosis (31,37), and cell survival and proliferation (38,39). They have also been shown to contain metalloproteinases able to digest extracellular matrix components, thus probably contributing to tissue invasion (40).

In the present study, we analyzed expression of the H1° gene in murine oligodendrogliaoma cells in order to shed further light on possible functions of this linker histone variant which still remains incompletely understood.

Materials and methods

Experimental animals. Wistar rats (Harlan, Udine, Italy) were housed in the animal house of STEBICEF Department, University of Palermo, Palermo, Italy. Procedures involving animals were in agreement with the European Community Council Directive 2010/63/EU and were approved by the University licensed veterinary. The number of animals used was minimized as much as possible.

Cell cultures and immunofluorescence. Astrocytes were isolated from brain cortices of 2-day old newborn rats, as previously described (41), and cultured in DME/Ham's F-12 (2:1), supplemented with 10% heat-inactivated fetal calf serum (Sigma-Aldrich, MO, USA), and 100,000 U penicillin, 100 mg streptomycin and 250 µg amphotericin B (Sigma-Aldrich) per liter.

G26/24 oligodendrogliaoma cells were cultured in DME/Ham's F-12 (2:1) medium supplemented with 10% fetal calf serum (FCS), and 100,000 U penicillin, 100 mg streptomycin and 250 µg amphotericin B (Sigma-Aldrich) per liter, for the same time. Cell cultures were maintained in humidified 5% CO2/95% air, at 37°C.

Some cultures of both astrocytes and oligodendrogliaoma cells were then progressively adapted to a medium known as Maat-medium (MM) (41) and maintained in culture for additional 3 days, as previously described (42,43).

For immunofluorescence, cells were fixed in 96% ethanol; then astrocytes were immunostained with rabbit anti-glial fibrillary acidic protein antibodies (GFAP; Sigma-Aldrich), and oligodendrogliaoma cells with goat anti-actin antibodies (Santa Cruz, CA, USA). The secondary antibodies were rhodamine- or fluorescein isothiocyanate-conjugated anti-rabbit- or anti-goat immunoglobulins (both from Sigma-Aldrich). Cells were finally observed under a fluorescence microscope (Olympus BX-50).

Northern blot analysis. Northern blot analysis was performed as previously described (16). Total RNA was purified from astrocytes cultured in NIH and in MM, and from G26/24 oligodendrogliaoma cells, according to Chomczynski and Sacchi (44), and were separated on 1.5% agarose, 6% formaldehyde denaturing gels, transferred to nylon membranes and hybridized to a 32P-labeled (Perkin-Elmer, MA, USA) fragment from the plasmid pmH1° (EMBL ID: X70685), cut with EcoRI.

Purification of total cell extracts. Cells were collected and homogenized in homogenization buffer (0.32 M sucrose; 50 mM sodium phosphate buffer, pH 6.5; 50 mM KCl, 0.5 mM spermine; 0.15 mM spermidine; 2 mM EDTA, and 0.15 mM EGTA), containing the protease inhibitors aprotinin (2 µg/ml), antipain (2 µg/ml), leupeptin (2 µg/ml), pepstatin A (2 µg/ml), benzamidine (1.0 mM), and phenylmethysulfonyl fluoride (1.0 mM), all purchased from Sigma-Aldrich. Protein concentration was determined according to Bradford (45).

Preparation of microvesicles from the cell culture medium. Vesicles were prepared from oligodendrogliaoma G26/24 and astrocyte subconfluent healthy cells grown in FCS-free medium, as previously described (33,37,40). After 24 h of culture, conditioned media were centrifuged at 2,000 x g for 10 min and then at 4,000 x g for 15 min. The supernantant was centrifuged at 105,000 x g (Ti60 Rotor, Beckman) for 90 min at 4°C. Pelleted vesicles were suspended with phosphate-buffered saline, pH 7.5 (PBS) and protein concentration in isolated vesicles was determined using Qubit® Protein Assay Kit (Invitrogen, OR, USA).

Western blot analysis. Proteins (15 µg of total cell extracts) were separated by electrophoresis on denaturing 12.5% polyacrylamide slab gels (SDS-PAGE) and transferred to PVDF membrane (Immobilon P, Millipore, MA, USA). The secondary antibodies were anti-mouse IgG (H+L), AP conjugate, and anti-rabbit IgG (Fc), AP conjugate (Promega Corporation, WI, USA).

Western blots were scanned by the ImageJ program and the values obtained were used to calculate the relative concentration of H1° in cell extracts and vesicles. The values obtained by this analysis were normalized respect to the value obtained with Hsc70 antibodies or by scanning the membrane stained with Ponceau Red. The measurements obtained from at least 3 independent experiments were finally used to calculate the relative concentrations of the analyzed proteins in the different conditions, as well as standard deviations (SD).

Preparation of in vitro transcripts and T1 RNase protection assay. 32P-radiolabeled H1° RNA was prepared as previously described (23), using as a template the plasmid pMH1° (46), which contains the H1° insert (EMBL ID: X70685). H1° RNA was mixed with total cell extracts (15 µg), prepared as described above. For the T1 protection assay, we used a previously described method (23) except that cross-linking of RNA to proteins was performed before incubation with T1 RNase (EC 3.1.27.3; Roche, Switzerland). RNA-protein complexes
were analyzed by SDS-PAGE. At the end of the run, the gel was directly exposed to X-ray film for autoradiography. The gels were also stained with Coomassie Brilliant Blue R-250 (Sigma-Aldrich), to confirm loading of equal amounts of proteins per lane.

Results

Expression of H1° linker histone in G26/24 oligodendroglioma cells and astrocytes. Astrocytes were cultured either in a serum-rich (NIH)- or in a serum-free medium (MM) for 72 h. As shown in Fig. 1, immunostaining of the astrocyte-specific GFAP evidenced a higher number of star-like brilliant cells when cells had been cultured in MM respect to cells cultured in NIH. Pictures of this kind suggested that astrocytes cultured in MM were a step forward, on the differentiation pathway, in respect to cells cultured in NIH. In agreement with this hypothesis, the linker histone H1°, a differentiation-specific histone variant, was expressed at higher levels in astrocytes cultured in MM (Fig. 2, lane 3) than in astrocytes cultured in NIH-medium (Fig. 2, lane 2). Concentration of H1° protein was even higher than in cortical fetal neurons, cultured in MM (Fig. 2, lane 1), already studied in the past (17). Once the relationship between H1° protein expression and differentiation was confirmed, we analyzed H1° expression in glial tumor cells. As shown in Fig. 1, there is no morphological difference between oligodendrogliaoma cells cultured in NIH or in MM. We found, however, that these cells (Fig. 2, lane 4) accumulate the linker histone H1° at levels comparable with those found in highly differentiated astrocytes cultured in MM (Fig. 2, lane 3). Expression of H1° histone in G26/24 cells did not change when cells were cultured in MM (data not shown).

Since in neurons we had found that the increase of H1° protein was accompanied by a decrease of the corresponding mRNA levels (16,17), we also investigated, by northern blot analysis, H1° RNA expression. As shown in Fig. 3, we found that the same correlation exists also in astrocytes: H1° mRNA almost disappears in differentiating astrocytes (Fig. 3, lane 2) while it is abundant in astrocytes cultured in NIH-medium (Fig. 3, lane 1). Interestingly, in G26/24 oligodendroglioma cells both H1° protein (Fig. 2, lane 4) and mRNA (Fig. 3, lane 3) are expressed at high levels.

H1° RNA-binding proteins in G26/24 oligodendroglioma cells and astrocytes. The fact that the concentration of H1° mRNA decreased in astrocytes with an inverse correlation to H1° protein accumulation suggested that in these brain cells, like in neurons and whole rat brain, concentration of H1° histone was largely regulated at the post-transcriptional level. Since this level of gene expression control involves a variety of RNA-binding proteins.
proteins, we tested astrocyte extracts for the presence of H1° RNA-binding factors. As shown in Fig. 4, in astrocytes cultured in the serum-rich medium (Astro, NIH) binding factors are present which forms a major complex of about 50 kDa with H1° RNA. No complex of the same apparent mass was evident in the serum-rich medium (Astro, NIH) binding factors are present which forms a major complex of about 50 kDa with H1° RNA. No complex of the same apparent mass was evident in either astrocytes (Fig. 4a, Astro, MM) or neurons (Fig. 4a, Neu) cultured in MM. A major signal of about 50 kDa, and several minor ones, due to formation of H1° RNA-protein complexes, were also visible when G26/24 cell extracts were analyzed (Fig. 4b, O).

**H1° histone protein is shed by G26/24 cells through extracellular membrane vesicles.** G26/24 cells were recently found to shed extracellular membrane vesicles which can induce neuronal death (31,37) and contain a variety of cell proteins, among which extracellular matrix metalloproteases (40). In the present study, we also tested the presence of H1° histone in the vesicles. As shown in Fig. 5a, H1° is clearly present in the vesicles shed from G26/24 tumor cells but not in those shed by astrocytes. This analysis also confirmed the already reported presence of Hsc70 in vesicles shed from oligodendroglioma cells (37). Moreover, in the present study, we report that Hsc70 is also found in vesicles released from astrocytes (Fig. 5a). The statistical analysis performed on at least three different experiments (Fig. 5b) suggested that H1° is specifically enriched in vesicles: the relative proportion of H1° in vesicles (V) shed from G26/24 (O), respect to lysates (L) of the same cells, is indeed clearly higher in comparison with the relative proportion of Hsc70 in the same samples (Fig. 5c).

**Discussion**

The transcriptional potential of the cell nucleus is determined by availability of transcription factors as well as by the structural organization of genes in the context of chromatin. Even in terminally differentiated cells, specific regions of chromatin are remodelled to allow transcription activation or repression in response to intra- and/or extracellular signals. One of the mechanisms at the basis of chromatin dynamics is likely to be synthesis and incorporation of replacement histone variants, such as the core H3.3 histone and the linker H1° histone. In developing brain, as well as in fetal neurons differentiating in culture, H1° mRNA is progressively down-regulated in vivo at the time of rat brain maturation (16,17), with an inverse correlation to synthesis and accumulation of H1° protein, although the transcriptional activity of H1° gene is unaffected by terminal differentiation. This finding suggested that H1° expression in the brain was mostly regulated at the post-transcriptional level (17).

As shown in the present study, like in the whole brain and in isolated neurons, the linker histone H1° is expressed at higher levels in astrocytes cultured in a serum-free medium (MM) in which they acquire a clearly differentiated star-like appearance. In these cells, concentration of H1° protein is even higher than in cortical fetal neurons, cultured in the same medium. Moreover, like in neurons, H1° mRNA almost disappears with protein accumulation. It is likely that H1° mRNA is destabilized and degraded at higher rates concomitant with its increased engagement with the translational apparatus.

How can the availability of H1° mRNA to the ribosomes be controlled? We already knew that a variety of H1° mRNA-binding factors exist in the rat brain (22-30). Now we evidenced an RNA-protein covalent complex of about 50 kDa, which disappears when astrocytes are cultured in differentiating conditions. Since the T1 RNase assay is a functional test, we cannot say whether the factor disappears during differentiation or undergoes a post-translational modification that abolishes its binding activity.
Unexpectedly, in glial tumor cells concentration of both H1˚ mRNA and protein is very high and does not correlate with a decrease of proliferation rate. Thus the still unknown mechanism responsible for the inverse correlation between H1˚ mRNA and protein concentrations does not work in oligodendroglioma cells. Complexes with a size similar to the complex seen in undifferentiated astrocytes do form, but they are probably not able to block access to ribosomes. Most importantly, synthesis of a high level of H1˚ histone protein does not correlate with a decrease of proliferation rate.

Since we already knew that G26/24 cells actively shed extracellular microvesicles (MVs), which contain a variety of proteins (31,37,40), we asked whether oligodendroglioma cells are able to unload H1˚ into the extracellular environment. Here we report that indeed H1˚ histone is present in MVs shed by oligodendroglioma cells but not in those shed by astrocytes, even if both populations of MVs contain, for example, Hsc70 chaperone. Although the role of shedding in tumor cells is not yet completely understood, it could be also involved in eliminating proteins from cells (such as the H1˚ histone) that could be otherwise able to counteract proliferation.

Acknowledgements

This study was supported by a special grant of Merck Serono S.p.A. to G.S. and by the University of Palermo (Università degli Studi di Palermo, Palermo, Italy; ex 60%). P.S. received a PhD studentship from the University of Palermo.

References

1. Allan J, Hartman PG, Crane-Robinson C and Aviles FX: The structure of histone H1 and its location in chromatin. Nature 288: 675-679, 1980.
2. Bates DL, Butler PJ, Pearson EC and Thomas JO: Stability of the higher-order structure of chicken-erythrocyte chromatin in solution. Eur J Biochem 119: 469-476, 1981.
3. Huang HC and Cole RD: The distribution of H1 histone is non-uniform in chromatin and correlates with different degrees of condensation. J Biol Chem 259: 14237-14242, 1984.
4. Hill DA: Influence of linker histone H1 on chromatin remodeling. Biochem Cell Biol 79: 317-324, 2001.
5. Fan Y, Nikitina T, Zhao J, Fleury TJ, Bhattacharyya R, Bouhassira EE, Stein A, Woodcock CL and Skoulitchi AI: Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell 123: 1199-1212, 2005.
6. Crane-Robinson: How do linker histones mediate differential gene expression? Bioessays 21: 367-371, 1999.
7. Izzo A, Kameniarz K and Schaefer R: The histone H1 family: specific members, specific functions? Biol Chem 389: 333-343, 2008.
8. Marzullo WF, Gongudi P, Woods RK, Jin J and Maltais LJ: The human and mouse replication-dependent histone genes. Genomics 80: 487-498, 2002.
9. Huppel N and Donecke D: Histone H1 and its isoforms. Contribution to chromatin structure and function. Gene 431: 1-12, 2009.
10. Kowalski A and Pulyga J: Linker histone subtypes and their allelic variants. Cell Biol Int 36: 981-996, 2012.
11. Clausell J, Huppel N, Hale TK, Donecke D and Beato M: Histone H1 subtypes differentially modulate chromatin condensation without preventing ATP-dependent remodeling by SWI/SNF or NURF. PLoS One 4: e0007243, 2009.
12. Fan Y, Syrotkin A, Russel RG, Ayala J and Skoulitchi AI: Individual somatic H1 subtypes are dispensable for mouse development even in mice lacking the H1(0) replacement subtypes. Mol Cell Biol 21: 7933-7943, 2001.
13. Yang SM, Byung JK, Norwood Toro L and Skoulitchi AI: H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. Proc Natl Acad Sci USA 110: 1708-1713, 2013.
14. Zlatanova J and Doenecke D: Histone H1 zero: a major player in cell differentiation. FASEB J 8: 1260-1268, 1994.
15. Gabrilovich DI, Cheng P, Fan Y, Yu B, Nikitina E, Sirotinik A, Shurin M, Oyama T, Adachi Y, Nadaf S, Carbone DP and Skoulitchi AI: H1˚ histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. J Leukoc Biol 72: 285-296, 2002.
16. Castiglia D, Castellini A, Scuturro M, Nastasi T and Di Liegro I: H1˚ and H3.3B mRNA levels in developing rat brain. Neurochem Res 19: 1531-1537, 1994.
17. Scuturro M, Castellini A, Castiglia D, Nastasi T and Di Liegro I: Post-transcriptional regulation of H1˚ and H3.3 histone genes in differentiating rat cortical neurons. Neurochem Res 20: 969-976, 1995.
18. Burd CG and Dreyfuss G: Conserved structures and diversity of functions of RNA-binding proteins. Science 265: 615-621, 1994.
19. Hentze MW: Translational regulation: versatile mechanisms for metabolic and developmental control. Curr Opin Cell Biol 7: 393-398, 1995.
20. Siomi H and Dreyfuss G: RNA-binding proteins as regulators of gene expression. Curr Opin Gen Dev 7: 345-353, 1997.
21. Derrigo M, Castelli A, Savettieri G and Di Liegro I: RNA-protein interactions in the control of stability and localization of messenger RNA (Review). Int J Mol Med 5: 115-123, 2000.
22. Castiglia D, Scuturro M, Nastasi T, Castellini A and Di Liegro I: PIPPin, a putative RNA-binding protein, specifically expressed in the rat brain. Biochem Biophys Res Commun 218: 390-394, 1996.
23. Scuturro M, Nastasi T, Raimondi L, Bellafiore M, Castellini A and Di Liegro I: H1˚ RNA-binding proteins specifically expressed in the rat brain. J Biol Chem 273: 22788-22791, 1998.
24. Nastasi T, Scuturro M, Bellafiore M, Raimondi L, Becacci S, Castellini A and Di Liegro I: PIPPin is a brain-specific protein that contains a cold-shock domain and binds specifically to H1˚ and H3.3 mRNAs. J Biol Chem 274: 24087-24093, 1999.
25. Raimondi L, D’Asaro M, Proia P, Nastasi T and Di Liegro I: RNA-binding activity of PIPPin requires the entire protein. J Cell Mol Med 7: 35-42, 2003.
26. Scuturro M, Sala A, Cutrona G, Raimondi L, Cammino G, Fontana S, Pucci-Minafra I and Di Liegro I: Purification by affinity chromatography of H1˚ RNA-binding proteins from rat brain. Int J Mol Med 11: 509-513, 2003.
27. Bono E, Compagno V, Proia P, Raimondi L, Schiera G, Favaloro V, Campo V, Donatelli M and Di Liegro I: Thyroid hormones induce sumoylation of the cold shock domain-containing protein PIPPin in developing rat brain and in cultured neurons. Endocrinology 148: 252-257, 2007.
28. Sala A, Scuturro M, Proia P, Schiera G, Balistreri E, Aflalo-Rattenbach R and Di Liegro I: Cloning of a rat-specific long PCP4/PIMP isoform (LP1). Int J Mol Med 19: 501-509, 2007.
29. Saladino P, Di Liegro CM, Proia P, Sala A, Schiera G, Lo Cicero A and Di Liegro I: RNA-binding activity of the rat calmodulin-binding PEP-19 protein and of the long Pep-19 isoform. Int J Mol Med 29: 141-145, 2012.
30. Di Liegro CM, Schiera G, Proia G, Paladino P and Di Liegro I: Identification in the rat brain of a set of nuclear proteins interacting with H1˚ mRNA. Neuroscience 229: 71-76, 2013.
31. D’Agostino S, Salamone M, Di Liegro I and Vittorelli ML: Membrane vesicles shed by oligodendroglialoma cells induce neuronal apoptosis. Int J Oncol 29: 1075-1085, 2006.
32. Schiera G, Proia P, Alberti C, Mineo M, Savettieri G and Di Liegro I: Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. J Cell Mol Med 11: 1384-1394, 2007.
33. Proia P, Schiera G, Mineo M, Ingrassia AM, Santoro G, Savettieri G and Di Liegro I: Astrocytes shed extracellular vesicles that contain fibroblast growth factor-2 and vascular endothelial growth factor. Int J Mol Med 23: 294-298, 2009.
34. D’Asati E, Garmer D, Lee TH, Montermini L, Meehan B and Robinson RJ: Exosomes: extracellular vesicles important in intercellular communication. J Proteomics 73: 1907-1920, 2010.
37. Lo Cicero A, Schiera G, Proia P, Saladino P, Savettieri G, Di Liegro CM and Di Liegro I: Oligodendroglialoma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int J Oncol 39: 1353-1357, 2011.

38. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B and Camussi G: Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110: 2440-2448, 2007.

39. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM and Breakefield XO: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476, 2008.

40. Lo Cicero A, Majkowski I, Nagase H, Di Liegro I and Troeberg L: Microvesicles shed by oligodendroglialoma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biol 31: 229-233, 2012.

41. Cestelli A, Savettieri G, Ferraro D and Vitale F: Formulation of a novel synthetic medium for selectively culturing rat CNS neurons. Brain Res 354: 219-227, 1985.

42. Schiera G, Bono E, Raffa MP, Gallo A, Pitarresi GL, Di Liegro I and Savettieri G: Synergistic effects of neurons and astrocytes on differentiation of brain capillary endothelial cells in culture. J Cell Mol Med 7: 165-170, 2003.

43. Schiera G, Sala S, Gallo A, Raffa MP, Pitarresi GL, Savettieri G and Di Liegro I: Permeability properties of a three-cell type in vitro model of Blood-Brain barrier. J Cell Mol Med 9: 373-379, 2005.

44. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.

45. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254, 1978.

46. Castiglia D, Grisini R, Scaturro M and Di Liegro I: Cloning and analysis of cDNA for rat histone H1. Nucleic Acids Res 21: 1674, 1993.